Simple blood draws could predict colon cancer treatment success
NCT ID NCT07701408
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study investigates whether two blood-based biomarkers—circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP)—can predict how well colon cancer responds to pre-surgery therapy. About 80 adults with stage III colon cancer will provide extra blood samples before, during, and after standard treatment and surgery. Researchers will analyze changes in these biomarkers and compare them to imaging and pathology results to see if they can forecast treatment outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to guide colon cancer treatment, potentially reducing unnecessary surgeries or chemotherapy.
- What could go wrong
- This is an early-stage biomarker study with only 80 participants, so results may not be conclusive or widely applicable. The approach is observational and does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Dye-Free laser imaging could replace standard dye in colorectal surgery
- Polyp recurrence after colon cancer surgery: a clue to better Follow-Up?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Giving cancer patients a say in genetic results may boost knowledge and satisfaction